Company News

Polaris Group ADI-PEG20 on the cover of AACR journals

Molecular Cancer Therapeutics

Pancreatic cancer is notoriously difficult to treat. One potential opportunity for targeting pancreatic cancer is through its modified amino acid metabolism. Specifically, depriving arginine-dependent tumor cells of arginine can lead to cell death. To achieve this, a polyethylene glycol (PEG)-conjugated arginine deiminase construct (ADI-PEG20) was previously designed and tested as a monotherapy in clinical studies with limited success.

Read more..

Scroll to Top
This site is registered on as a development site.